This relatively new Prolia side effect, hypocalcemia, first came to our attention in late 2022 with the release of this November 22, 2022 document, “FDA Drug Safety Communication: FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)”. From that November 2022 FDA Drug Safety … [Read more...]
Prolia & Xgeva: QT Interval Prolongation Associated With Hypocalcemia
Denosumab is the active ingredient for Prolia as well as Xgeva, with Prolia being a treatment for osteoporosis and osteopenia, and Xgeva being a drug used for the prevention of skeletal-related events in adults with bone metastases from solid tumors. Both Prolia and Xgeva come from biotech pharmaceutical company Amgen Inc. An emerging drug … [Read more...]